T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study.
Gallot G, Vollant S, Saïagh S, Clémenceau B, Vivien R, Cerato E, Bignon JD, Ferrand C, Jaccard A, Vigouroux S, Choquet S, Dalle JH, Frachon I, Bruno B, Mothy M, Mechinaud F, Leblond V, Milpied N, Vié H.
Gallot G, et al. Among authors: vigouroux s.
J Immunother. 2014 Apr;37(3):170-9. doi: 10.1097/CJI.0000000000000031.
J Immunother. 2014.
PMID: 24598452
Clinical Trial.